EP4232046A4 - Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit - Google Patents

Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit Download PDF

Info

Publication number
EP4232046A4
EP4232046A4 EP21803262.1A EP21803262A EP4232046A4 EP 4232046 A4 EP4232046 A4 EP 4232046A4 EP 21803262 A EP21803262 A EP 21803262A EP 4232046 A4 EP4232046 A4 EP 4232046A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compositions
dissolution rate
compositions prepared
milling method
dry milling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21803262.1A
Other languages
English (en)
French (fr)
Other versions
EP4232046A1 (de
Inventor
Levent ÖNER
Hakan EROGLU
Aslihan Arslan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hacettepe Ueniversitesi
Original Assignee
Hacettepe Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hacettepe Ueniversitesi filed Critical Hacettepe Ueniversitesi
Publication of EP4232046A1 publication Critical patent/EP4232046A1/de
Publication of EP4232046A4 publication Critical patent/EP4232046A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP21803262.1A 2020-10-26 2021-06-17 Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit Pending EP4232046A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/17034A TR202017034A2 (tr) 2020-10-26 2020-10-26 Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar
PCT/TR2021/050619 WO2021230849A1 (en) 2020-10-26 2021-06-17 Pharmaceutical compositions prepared by dry milling method and containing celecoxib with increased dissolution rate

Publications (2)

Publication Number Publication Date
EP4232046A1 EP4232046A1 (de) 2023-08-30
EP4232046A4 true EP4232046A4 (de) 2023-11-08

Family

ID=78524739

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21803262.1A Pending EP4232046A4 (de) 2020-10-26 2021-06-17 Durch trockenmahlverfahren hergestellte pharmazeutische zusammensetzungen mit celecoxib mit erhöhter auflösungsgeschwindigkeit

Country Status (3)

Country Link
EP (1) EP4232046A4 (de)
TR (1) TR202017034A2 (de)
WO (1) WO2021230849A1 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121321A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
CN102988296A (zh) * 2011-09-08 2013-03-27 江苏恒瑞医药股份有限公司 塞来昔布固体分散体及其制备方法
CN110840850A (zh) * 2018-07-24 2020-02-28 烟台药物研究所 一种高生物利用度的塞来昔布冻干口崩片及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103932988A (zh) * 2009-04-24 2014-07-23 伊休蒂卡有限公司 吲哚美辛的新剂型

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121321A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
CN102988296A (zh) * 2011-09-08 2013-03-27 江苏恒瑞医药股份有限公司 塞来昔布固体分散体及其制备方法
CN110840850A (zh) * 2018-07-24 2020-02-28 烟台药物研究所 一种高生物利用度的塞来昔布冻干口崩片及其制备方法

Also Published As

Publication number Publication date
EP4232046A1 (de) 2023-08-30
TR202017034A2 (tr) 2021-09-21
WO2021230849A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
EP4126879A4 (de) Verbindungen, pharmazeutische zusammensetzungen und verfahren zur herstellung von verbindungen und deren verwendung
EP3746076A4 (de) Zusammensetzung und verfahren zur verringerung der chemotherapie-induzierten neutropenie über die verabreichung von plinabulin und einem g-csf-mittel
EP4003369A4 (de) Adenosinderivat und pharmazeutische zusammensetzung damit
SG11202011886TA (en) PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING GLUCOKINASE ACTIVATOR AND a-GLUCOSIDASE INHIBITOR, PREPARATION METHODS THEREFOR AND USES THEREOF
EP3604301A4 (de) 4-pyridonverbindung oder salz davon und pharmazeutische zusammensetzung und formulierung damit
EP3312175A4 (de) Heteroarylderivat oder pharmazeutisch unbedenkliches salz davon, herstellungsverfahren dafür, und pharmazeutische zusammensetzung zur prävention oder behandlung von erkrankungen, die mit pi3-kinasen assoziiert sind, die diese als wirkstoff enthalten
EP4035657A4 (de) Wirkstoffzusammensetzung mit abirateronacetat und verfahren zu ihrer herstellung und ihre verwendung
EP4134366A4 (de) 3-azabicycloalkyl-derivat und pharmazeutische zusammensetzung damit
EP3980412A4 (de) 1-pyrazolyl,5-, 6-disubstituierte indazolderivate als lrrk2-inhibitoren, pharmazeutische zusammensetzungen und deren verwendung
EP3743074A4 (de) Zusammensetzung und verfahren zur reduktion von thrombozytopenie über die verabreichung von plinabulin
EP3762392A4 (de) Thienopyridinderivate und pharmazeutische zusammensetzung damit
EP3714887A4 (de) Pharmazeutische zusammensetzung zur topischen verabreichung und herstellungsverfahren dafür
EP3825308A4 (de) Verbindung, zusammensetzung und ihre verwendung zur herstellung eines arzneimittels
EP3946547A4 (de) Vorrichtungen und verfahren zur abgabe von pharmazeutischen zusammensetzungen
EP3694330A4 (de) Indazolyl-spiro[2.2]pentancarbonitrilderivate als lrrk2-inhibitoren, pharmazeutische zusammensetzungen und deren verwendung
EP3725297A4 (de) Orale pharmazeutische zusammensetzung mit pemetrexed und verfahren zu ihrer herstellung
IL285421A (en) History of indazolyl-isoxazole, their preparation and pharmaceutical preparations containing them
EP3694331A4 (de) Indazolyl-spiro[2,3]hexancarbonitrilderivate als lrrk2-inhibitoren, pharmazeutische zusammensetzungen und deren verwendung
EP4023227A4 (de) Pharmazeutische zusammensetzung und verabreichung davon
EP3908251A4 (de) Arzneimittelabgabezusammensetzungen und verwendungen davon
EP3866767A4 (de) Pharmazeutische zusammensetzung zum einnehmen mit aminopyrimidinderivat oder salz davon
EP3982942A4 (de) Verfahren zur wirkstofffreisetzung und zusammensetzungen
EP3981389A4 (de) Topisch verabreichte pharmazeutische zusammensetzung in gelöster form mit efinaconazol
EP3452441A4 (de) Alpha-truxillinsäure-derivate und pharmazeutische zusammensetzungen daraus
EP4223759A4 (de) Pyrazolopyridazinonverbindung sowie pharmazeutische zusammensetzung und verwendung davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20231010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101ALI20231004BHEP

Ipc: A61K 31/415 20060101ALI20231004BHEP

Ipc: A61K 31/635 20060101AFI20231004BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)